New pricing and payment models for cost-effective and affordable health innovations

Closed

Programme Category

EU Competitive Programmes

Programme Name

Horizon Europe (2021-2027)

Programme Description

Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.

Programme Details

Identifier Code

HORIZON-HLTH-2022-IND-13-03

Call

New pricing and payment models for cost-effective and affordable health innovations

Summary

Applicants for this prosposal are requested to propose new value-based pricing and reimbursement models that can help ensure equitable access to effective, efficient, affordable, and sustainable health technologies, including medicines, while supporting innovation and industrial competitiveness.
The proposals should not be limited to the study of cost-effectiveness analyses and thresholds in decision-making. They should also address long term intended and unintended consequences of pricing and reimbursement decisions.

Detailed Call Description

Applicants should propose activities in all of the following areas:

  • Affordability of health innovations.
  • Variety of pricing/payment schemes in the EU.
  • Cost-effectiveness and budget impact (including life-time indirect medical costs).
  • Impact of payment schemes (e.g. pay-for-performance/multi-annual instalments) on long-term competition in health technology markets, in particular the pharmaceutical market.
  • Potential influence of post-launch evidence-generation plans agreed with regulators and downstream decision makers (HTAs, payers) on the payment models.
  • Transparent and comprehensive assessment of technology and medicine development costs, taking into account public investments and incremental character of some innovations (e.g. new indications).
  • Development, integration and harmonisation of tools that allow for validation and revision of clinical evidence and cost-effectiveness, and long-term financial planning for effective and transparent decision-making.
  • New methods for definition of cost-effectiveness thresholds, integration of greener production and environmental impact, rational applications in real world contexts, comparative analysis of influence in decision-making and influence in the formulation of prices of technologies.
  • Potential equity issues derived by payment models and the measures for their mitigation.

Call Total Budget

€15,00 million

Financing percentage by EU or other bodies / Level of Subsidy or Loan

100%

Contribution per project: €5,00 million

Thematic Categories

  • Health
  • Research, Technological Development and Innovation

Eligibility for Participation

  • Central Government
  • Large Enterprises
  • Private Bodies
  • Researchers/Research Centers/Institutions
  • State-owned Enterprises

Eligibility For Participation Notes

  • Health authorities and insurers
  • Health industries
  • Patients and health care providers
  • Health authorities, insurers and health care providers

Call Opening Date

06/10/2021

Call Closing Date

21/04/2022

National Contact Point(s)

Research and Innovation Foundation
29a Andrea Michalakopoulou, 1075 Nicosia
P.O.Box 23422, 1683 Nicosia
Telephone: +357 22205000
Email Address: support@research.org.cy
Website: https://www.research.org.cy/en/

Mr Marinos Fotiadis
Contact Phone: 22 205 048
E-mail: mphotiades@research.org.cy
Website: https://www.research.org.cy/

Dr Ioannis Theodorou
Contact Phone: 22 205 038
E-mail: itheodorou@research.org.cy
Website: https://www.research.org.cy/

(Publish Date: 26/11/2021-for internal use only)

EU Contact Point

European Commission, Directorate-General for Research and Innovation

https://ec.europa.eu/info/departments/research-and-innovation_en#contact